Meeting
2012 ASCO Annual Meeting
Phase I study of weekly oral docetaxel (ModraDoc001) plus ritonavir in patients with advanced solid tumors.
Authors
Serena Marchetti
Netherlands Cancer Institute, Amsterdam, Netherlands
Serena Marchetti , Frederik Stuurman , Stijn Koolen , Johannes Moes , Jeroen Hendrikx , Bas Thijssen , Alwin D.R. Huitema , Bastiaan Nuijen , Hilde Rosing , Marianne Keessen , Emile E. Voest , M. Mergui-Roelvink , Jos H. Beijnen , Jan H. M. Schellens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Cytotoxic Agents
Clinical Trial Registration Number
ISRCTN32770468
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2550)
DOI
10.1200/jco.2012.30.15_suppl.2550
Abstract #
2550
Poster Bd #
2F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2012 ASCO Annual Meeting
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
First Author: Carlos Becerra